Ryan Grayburn, DO
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MINPI 1841415098
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,268 of the $4,489 with a category attached, or 72.8%. 19 manufacturers reported payments, led by One Lambda, Inc. at 36.0% of the total. Reporting peaked in 2024 at $1,825 and has fallen 55.6% since, to $811 in 2025.
Across 74 payments — averaging $60.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- One Lambda, Inc.$2K
- Abbott$1K
- Cvrx, Inc.$292
- Novartis$192
- Medtronic$179
- Shockwave Medical, Inc$177
- plus $595 from 13 others
Across 1 payment — averaging $23.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$23
What the payments were for
- Travel & lodging$1,22127%
- Food & beverage$3,26873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| One Lambda, Inc. | 3 | $1,614 |
| Abbott | 23 | $1,440 |
| Cvrx, Inc. | 2 | $292 |
| Novartis | 11 | $192 |
| Medtronic | 3 | $179 |
| Shockwave Medical, Inc | 6 | $177 |
| AstraZeneca | 2 | $134 |
| Pfizer | 5 | $129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $103 |
| Boston Scientific | 3 | $59 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Boehringer Ingelheim | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Merck | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,489 in reported general payments places this provider in the 55th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 130 | $2,876,060 |
| EntrestoSacubitril/Valsartan | 264 | $301,806 |
| EliquisApixaban | 148 | $155,925 |
| JardianceEmpagliflozin | 68 | $77,857 |
| FarxigaDapagliflozin Propanediol | 69 | $59,030 |
| XareltoRivaroxaban | 15 | $22,611 |
| Metoprolol Succinate | 241 | $5,965 |
| Torsemide | 178 | $5,830 |
| Potassium Chloride | 81 | $4,015 |
| Spironolactone | 279 | $2,593 |
| Carvedilol | 125 | $2,103 |
| Eplerenone | 27 | $1,753 |
| Isosorbide Dinitrate | 19 | $1,655 |
| Furosemide | 134 | $1,235 |
| Atorvastatin Calcium | 61 | $1,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $129 | $3,031,985278 claims |
| NovartisEntresto | $192 | $301,806264 claims |
| Boehringer IngelheimJardiance | $23 | $77,85768 claims |
| AstraZenecaFarxiga | $134 | $59,03069 claims |
| Johnson & JohnsonXarelto | $18 | $22,61115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
Other advanced heart failure and transplant cardiology in Grand Rapids
- David FerminGrand Rapids$105K
- Michael DickinsonGrand Rapids$80K
- Sangjin LeeGrand Rapids$25K
- Matthew GonzalezGrand Rapids$22K
- Renzo Loyaga-RendonGrand Rapids$5K
- Milena JaniGrand Rapids$3K
- Jennifer CowgerDetroit$165K
- Thomas CascinoAnn Arbor$39K
- Keith AaronsonAnn Arbor$22K
- Waleed Al-DarziDetroit$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.